These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 37331197)

  • 21. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
    Franco V; Perucca E
    Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex.
    Espinosa-Jovel C; Riveros S; Bolaños-Almeida C; Salazar MR; Inga LC; Guío L
    Seizure; 2023 Nov; 112():72-76. PubMed ID: 37769547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Source of cannabinoids: what is available, what is used, and where does it come from?
    Specchio N; Pietrafusa N; Cross HJ
    Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
    Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
    Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
    Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
    Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
    Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
    Lattanzi S; Trinka E; Striano P; Zaccara G; Del Giovane C; Nardone R; Silvestrini M; Brigo F
    Epilepsia; 2020 Jun; 61(6):1090-1098. PubMed ID: 32452532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabidiol use in patients with Dravet syndrome and Lennox-Gastaut syndrome: experts' opinions using a nominal group technique (NGT) approach.
    Bonanni P; Ragona F; Fusco C; Gambardella A; Operto FF; Parmeggiani L; Sartori S; Specchio N
    Expert Opin Pharmacother; 2023 Apr; 24(5):655-663. PubMed ID: 37021712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome.
    Iannone LF; Arena G; Battaglia D; Bisulli F; Bonanni P; Boni A; Canevini MP; Cantalupo G; Cesaroni E; Contin M; Coppola A; Cordelli DM; Cricchiuti G; De Giorgis V; De Leva MF; De Rinaldis M; d'Orsi G; Elia M; Galimberti CA; Morano A; Granata T; Guerrini R; Lodi MAM; La Neve A; Marchese F; Masnada S; Michelucci R; Nosadini M; Pilolli N; Pruna D; Ragona F; Rosati A; Santucci M; Spalice A; Pietrafusa N; Striano P; Tartara E; Tassi L; Papa A; Zucca C; Russo E; Mecarelli O;
    Front Neurol; 2021; 12():673135. PubMed ID: 34093420
    [No Abstract]   [Full Text] [Related]  

  • 31. Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.
    Kühne F; Becker LL; Bast T; Bertsche A; Borggraefe I; Boßelmann CM; Fahrbach J; Hertzberg C; Herz NA; Hirsch M; Holtkamp M; Janello C; Kluger GJ; Kurlemann G; Lerche H; Makridis KL; von Podewils F; Pringsheim M; Schubert-Bast S; Schulz J; Schulze-Bonhage A; Steinbart D; Steinhoff BJ; Strzelczyk A; Syrbe S; De Vries H; Wagner C; Wagner J; Wilken B; Prager C; Klotz KA; Kaindl AM
    Epilepsia Open; 2023 Jun; 8(2):360-370. PubMed ID: 36693811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis.
    Devi N; Madaan P; Ameen R; Sahu JK; Bansal D
    Seizure; 2022 Jul; 99():164-175. PubMed ID: 35487871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
    Bergmann KR; Broekhuizen K; Groeneveld GJ
    Br J Clin Pharmacol; 2020 Feb; 86(2):380-385. PubMed ID: 31657863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabis for the Treatment of Epilepsy: an Update.
    Gaston TE; Szaflarski JP
    Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study.
    Marshall J; Skrobanski H; Moore-Ramdin L; Kornalska K; Swinburn P; Bowditch S
    J Child Neurol; 2023 May; 38(6-7):394-406. PubMed ID: 37455396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Cagnetti C; Trinka E; Silvestrini M
    CNS Drugs; 2018 Oct; 32(10):905-916. PubMed ID: 30132269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.
    Lo SH; Lloyd A; Marshall J; Vyas K
    Clin Ther; 2021 Nov; 43(11):1861-1876.e16. PubMed ID: 34774333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2022; 68(10):1345-1357. PubMed ID: 36417631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
    Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
    Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy.
    Georgieva D; Langley J; Hartkopf K; Hawk L; Margolis A; Struck A; Felton E; Hsu D; Gidal BE
    Epilepsy Behav; 2023 Apr; 141():109159. PubMed ID: 36893722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.